Scholars Central

Conference abstractPublished 26 Oct 2015

Biosimilars: Challenges and developments

Authors: Samer M Al-Hulu

Al-Qasim Green University, Iraq

Ask about this article

Abstract

Select any words in the title or abstract, or press this and choose a sentence.

Biosimilars are âÂ?Â?similar but not the sameâÂ? to the original biologic innovator product. Some of challenges that effect on biosimilars development such as Verification of similarity, not having of unique name, findings of biosimilars guidelines, safety, labeling of biosimilar and regulatory framework for assessing of biosimlar. Development of biosimilars achieved by finding of unique name, using of powerful analytical tools for biosimilars comparability to the reference, quality by design studies, using of statistical method for reducing of simple size of bio-similar clinical trial and post-marketing surveillance studies to establish biosimilar safety, and single use bioprocessing (single use bioreactor) for biosimilar production for meeting their clinical manufactures. Pharmacovigilance programs are important for establishing clinical databases. A new generation of biosimilars such as bio-betters, monoclonal antibody biosimilars are having more acceptability and are approved.

Ask about this article

Answers come only from this article's title, abstract and keywords, each sentence pointing to where it comes from. Your question is sent to OpenAI to write the answer. Scholars Central does not store it.

Try:

Similar by topic

More from this journal

The newest in Journal of Bioanalysis & Biomedicine.

All its articles

Follow

New articles from what you follow go into your email digest, once you agree to alert emails.

  • JournalJournal of Bioanalysis & Biomedicine
  • BylineArticles whose byline prints “Samer M Al-Hulu”

For authors and organisers

Publish, present and keep up with your field

Find the right journal for your paper and submit your manuscript.

Photo: Pexels